These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. Wrona A; Dziadziuszko R; Jassem J Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200 [TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Jamal-Hanjani M; Spicer J Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408 [TBL] [Abstract][Full Text] [Related]
8. Treatment of brain metastases from lung cancer: chemotherapy. Schuette W Lung Cancer; 2004 Aug; 45 Suppl 2():S253-7. PubMed ID: 15552807 [TBL] [Abstract][Full Text] [Related]
9. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. Sekine A; Satoh H Med Oncol; 2017 Jul; 34(7):121. PubMed ID: 28555261 [TBL] [Abstract][Full Text] [Related]
10. [Management of brain metastases for lung cancer patients]. Barlesi F; Khobta N; Tallet A; Goncalves A; Azria D; Spano JP; Carpentier AF; Régis J; Metellus P Bull Cancer; 2013 Mar; 100(3):303-8. PubMed ID: 23518334 [TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058 [TBL] [Abstract][Full Text] [Related]
13. Systemic therapy for lung cancer brain metastases: a rationale for clinical trials. Oh Y; Stewart DJ Oncology (Williston Park); 2008 Feb; 22(2):168-78; discussion 178, 183, 188 passim. PubMed ID: 18409662 [TBL] [Abstract][Full Text] [Related]
14. Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer. Wardak Z; Choy H J Clin Oncol; 2016 Dec; 34(34):4064-4065. PubMed ID: 27863198 [No Abstract] [Full Text] [Related]
15. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases. Song Z; Zhang Y J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883 [TBL] [Abstract][Full Text] [Related]
16. Medical treatment of brain metastases from lung cancer. Cappuzzo F Suppl Tumori; 2002; 1(4):S58-9. PubMed ID: 12415823 [No Abstract] [Full Text] [Related]
17. [ANOCEF guidelines for the management of brain metastases]. Le Rhun É; Dhermain F; Noël G; Reyns N; Carpentier A; Mandonnet E; Taillibert S; Metellus P; Cancer Radiother; 2015 Feb; 19(1):66-71. PubMed ID: 25666314 [TBL] [Abstract][Full Text] [Related]
19. Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases. Martínez P; Mak RH; Oxnard GR JAMA Oncol; 2017 Sep; 3(9):1274-1275. PubMed ID: 28520828 [TBL] [Abstract][Full Text] [Related]
20. Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. von Pawel J; Wagner H; Duell T; Poellinger B Onkologie; 2008 Mar; 31(3):123-6. PubMed ID: 18322416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]